Navigation Links
Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years

te-release paclitaxel-eluting stent is not approved for commercial distribution.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com .

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.


    CONTACT:  Paul Donovan

              508-650-8541 (office)

              508-667-5165 (mobile)

              Media Relations

              Boston Scientific Corporation


              Dan Brennan

              508-650-8538 (office)

              617-459-2703 (mobile)

              Investor Relations

              Boston Scientific Corporation

Boston Scientific Corporation

CONTACT: Media Relations, Paul Donovan, +1-508-650-8541, mobile,+1-508-667-5165, Investor Relations, Dan Brennan, +1-508-650-8538, mobile,+1-617-459-2703, both of Boston Scientific Corporation

Web site: http://www.bostonscientific.com/

Ticker Symbol: (NYSE:BSX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3

Related medicine technology :

1. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
2. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
3. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
4. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
5. Genetic Analysis Systems Enter the Clinical Mainstream
6. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
7. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
8. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
Post Your Comments:
(Date:9/22/2014)... , Sept. 22, 2014  Neuralstem, Inc. (NYSE MKT: ... site investigator at Emory University, presented long-term follow up ... neural stem cells in the treatment of amyotrophic lateral ... presentation, which occurred at the Annual Symposium on ALS ... , on Friday, and was not open to ...
(Date:9/22/2014)... , Sept. 22, 2014  Olympus, a global ... for medical and surgical procedures, among other core ... with Munich -based Brainlab to ... Navigation. This agreement applies to the US ... U.S. sales and all distribution outside the U.S. ...
(Date:9/22/2014)... 22, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... a phase I clinical trial in patients with ... tolerability, and immunogenicity of INO-3106. This immunotherapy targets ... aerodigestive cancers. Aerodigestive cancers affect the ... parts of the esophagus and windpipe. The unmet ...
Breaking Medicine Technology:Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4
... FOREST, Ill., Sept. 6, 2011 Hospira, Inc. ... in generic injectable pharmaceuticals, today announced positive results from ... erythropoietin (EPO) in patients with renal (kidney) dysfunction who ... equal pharmacokinetics, or blood level and distribution in the ...
... 2011 Johnson & Johnson (NYSE: JNJ ) ... Tuesday, September 13 th , at the Grand Hyatt New ... New York, NY.  Dominic Caruso, Vice President, Finance and Chief ... the company in a session scheduled at 10:20 a.m. (Eastern). ...
Cached Medicine Technology:Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 2Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 3
(Date:9/22/2014)... County, NY (PRWEB) September 22, 2014 ... joined the Department of Surgery at the Icahn School ... Sinai Doctors New York Group for Plastic Surgery gives ... Valley access to a team of world-renowned plastic surgeons ... Additionally, C. Andrew Salzberg, MD, who led NYGPS, was ...
(Date:9/22/2014)... very familiar "lub-dub" pattern that speeds up or slows ... itself isn,t as regular as you might think. In ... even at a "constant" heart rateand that variability, doctors ... heart rate variability (HRV) has been found to be ... heart failure and inflammation. For athletes, a drop in ...
(Date:9/22/2014)... WHO: LiveOps, Inc., the global ... solutions. , WHAT: The 10th annual Customer Response ... for the connected consumer. Constant change in technology ... challenges and opportunities for customer experience executives. The ... practices, network and learn from fellow attendees, speakers ...
(Date:9/22/2014)... By Tara Haelle ... (HealthDay News) -- Measuring how quickly a child,s brain ... according to a new study. Observing children,s ... is currently possible, the study authors reported. "The ... information is associated with autism severity is hugely promising," ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Medical ... for a three-day conference to discuss brain-related diseases ... injury from concussions and neurodegenerative disorders. , ... director affiliated with a Silverado memory care community ... dedicated expertise in memory care, hosts the annual ...
Breaking Medicine News(10 mins):Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3Health News:Variability keeps the body in balance 2Health News:Variability keeps the body in balance 3Health News:Variability keeps the body in balance 4Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2Health News:Brainwaves May Help Gauge Autism Severity: Study 2Health News:Brainwaves May Help Gauge Autism Severity: Study 3Health News:Brainwaves May Help Gauge Autism Severity: Study 4Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 3
... for delivering,albuterol, a fast-acting bronchial dilator, currently use propellants ... beginning December 31st,2009, or replacement HFA,s. Both propellants are ... at near-supersonic speeds. , ... stream of air by ejecting,the medication from a microfluidic ...
... of,Dermatology (Academy) today issued a statement in response to the ... the,relationship between the use of indoor tanning devices and development ... was submitted pursuant to Section,230 of the Food and Drug ... "The American Academy of Dermatology is pleased that ...
... University Medical Center and 10 other healthcare facilities in the ... from the National Institutes of Health to identify which rehabilitation ... traumatic brain injuries. Rush is the only center in Illinois ... this study is to isolate individual components of the range ...
... a disease that includes the buildup of fatty, ... is the underlying cause of heart attacks and strokes. ... has now demonstrated that a receptor for prostaglandin-E2 plays ... findings, reported this month in Cell Metabolism , ...
... 15 Aurora Health Care announced today that,the ... in southeastern Wisconsin, have chosen to join Aurora Medical Group. ... Lakes radiologists practice chiefly at Aurora hospitals and,clinics. , ... every day contribute to the quality,of the care we provide ...
... based data profiling, In-Stream profiling, data quality and MDM discovery solutions ... Migration Alliance (MMA), joining Microsoft Corp. and other key industry partners ... mainframe onto the Microsoft® platform. , ... Chicago, IL ...
Cached Medicine News:Health News:Next Safety Develops an Air-Based Asthma Medication Inhaler That Does Not Use a Refrigerant Propellant 2Health News:Next Safety Develops an Air-Based Asthma Medication Inhaler That Does Not Use a Refrigerant Propellant 3Health News:American Academy of Dermatology Issues Statement on FDA Report to Congress About Labeling Information on Indoor Tanning Devices 2Health News:Study to identify best rehabilitation therapies for patients with traumatic brain injuries 2Health News:Prostaglandin receptor key to atherosclerosis development 2Health News:Prostaglandin receptor key to atherosclerosis development 3Health News:Great Lakes Radiologists to Join Aurora Medical Group 2Health News:AMB New Generation Data Empowerment Joins Mainframe Migration Alliance 2Health News:AMB New Generation Data Empowerment Joins Mainframe Migration Alliance 3
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
... Millipore has developed a range ... to match specific water quality requirements. ... systems is designed to specifically target ... as HPLC, molecular biology and ICP-MS. ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... has developed a range of Milli-Q ... specific water quality requirements. Each of ... designed to specifically target contaminants detrimental ... molecular biology and ICP-MS. The systems ...
Medicine Products: